docetaxel anhydrous has been researched along with bexarotene in 6 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (bexarotene) | Trials (bexarotene) | Recent Studies (post-2010) (bexarotene) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 642 | 67 | 348 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | bexarotene (IC50) |
|---|---|---|---|
| Cytochrome P450 3A4 | Homo sapiens (human) | 5.9 | |
| Retinoic acid receptor RXR-alpha | Homo sapiens (human) | 0.632 | |
| Cytochrome P450 26B1 | Homo sapiens (human) | 5.9 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Talele, TT | 1 |
| Baggstrom, MQ; Fracasso, PM; Govindan, R; Read, W; Suresh, R; Wildi, JD | 1 |
| Collins, B; Hwang, J; Malik, SM; Marshall, J; Pishvaian, M; Ramzi, P | 1 |
| Bai, J; Chang, C; He, X; Hu, L; Li, G; Luo, J; Sun, Y; Ye, M; Zhang, D; Zhang, Y | 1 |
2 review(s) available for docetaxel anhydrous and bexarotene
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry.
Topics: Animals; Biological Products; Chemistry, Pharmaceutical; Humans | 2018 |
2 trial(s) available for docetaxel anhydrous and bexarotene
| Article | Year |
|---|---|
A phase I study of docetaxel and bexarotene.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Docetaxel; Drug Administration Schedule; Fatigue; Female; Humans; Male; Middle Aged; Nausea; Neoplasms; Taxoids; Tetrahydronaphthalenes | 2008 |
A phase I trial of bexarotene in combination with docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Docetaxel; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Survival Rate; Taxoids; Tetrahydronaphthalenes; Treatment Outcome; Young Adult | 2011 |
2 other study(ies) available for docetaxel anhydrous and bexarotene
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Targeting TR4 nuclear receptor with antagonist bexarotene increases docetaxel sensitivity to better suppress the metastatic castration-resistant prostate cancer progression.
Topics: Antineoplastic Agents; Apoptosis; Bexarotene; Biomarkers, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Receptors, Steroid; Receptors, Thyroid Hormone; Tumor Cells, Cultured | 2020 |